Takara Bio Stock Net Income
| TF2 Stock | EUR 6.10 0.25 4.27% |
As of the 19th of February, Takara Bio has the Semi Deviation of 1.7, coefficient of variation of 698.42, and Risk Adjusted Performance of 0.1215. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Takara Bio, as well as the relationship between them. Please validate Takara Bio jensen alpha, maximum drawdown, and the relationship between the information ratio and treynor ratio to decide if Takara Bio is priced more or less accurately, providing market reflects its prevalent price of 6.1 per share.
Takara Bio Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization 793.9 M | Enterprise Value Revenue 2.3751 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 1.3 B | 1.2 B | |
| Net Income Applicable To Common Shares | 22.8 B | 24 B | |
| Net Income | 1.2 B | 1.1 B |
Takara | Net Income |
The Net Income trend for Takara Bio offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Takara Bio is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Takara Bio's Net Income Growth Pattern
Below is the plot of the Net Income of Takara Bio over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Takara Bio financial statement analysis. It represents the amount of money remaining after all of Takara Bio operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Takara Bio's Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Takara Bio's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 1.04 B | 10 Years Trend |
|
Net Income |
| Timeline |
Takara Net Income Regression Statistics
| Arithmetic Mean | 4,094,320,147 | |
| Geometric Mean | 2,324,050,325 | |
| Coefficient Of Variation | 137.77 | |
| Mean Deviation | 3,897,063,478 | |
| Median | 1,470,000,000 | |
| Standard Deviation | 5,640,939,219 | |
| Sample Variance | 31820195.3T | |
| Range | 18.9B | |
| R-Value | 0.28 | |
| Mean Square Error | 31325993.3T | |
| R-Squared | 0.08 | |
| Significance | 0.28 | |
| Slope | 310,096,544 | |
| Total Sum of Squares | 509123124.4T |
Takara Net Income History
Takara Bio 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Takara Bio's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Takara Bio.
| 11/21/2025 |
| 02/19/2026 |
If you would invest 0.00 in Takara Bio on November 21, 2025 and sell it all today you would earn a total of 0.00 from holding Takara Bio or generate 0.0% return on investment in Takara Bio over 90 days. Takara Bio is related to or competes with NTG Nordic, Wyndham Hotels, Scandic Hotels, Nishi-Nippon Railroad, Park Hotels, BROADSTNET LEADL, and Mitsui Chemicals. Takara Bio Inc., together with its subsidiaries, operates as a biotechnology company in Japan, the United States, China,... More
Takara Bio Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Takara Bio's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Takara Bio upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.27 | |||
| Information Ratio | 0.1326 | |||
| Maximum Drawdown | 34.17 | |||
| Value At Risk | (2.88) | |||
| Potential Upside | 4.46 |
Takara Bio Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Takara Bio's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Takara Bio's standard deviation. In reality, there are many statistical measures that can use Takara Bio historical prices to predict the future Takara Bio's volatility.| Risk Adjusted Performance | 0.1215 | |||
| Jensen Alpha | 0.6459 | |||
| Total Risk Alpha | 0.4173 | |||
| Sortino Ratio | 0.2574 | |||
| Treynor Ratio | (0.94) |
Takara Bio February 19, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1215 | |||
| Market Risk Adjusted Performance | (0.93) | |||
| Mean Deviation | 2.3 | |||
| Semi Deviation | 1.7 | |||
| Downside Deviation | 2.27 | |||
| Coefficient Of Variation | 698.42 | |||
| Standard Deviation | 4.41 | |||
| Variance | 19.46 | |||
| Information Ratio | 0.1326 | |||
| Jensen Alpha | 0.6459 | |||
| Total Risk Alpha | 0.4173 | |||
| Sortino Ratio | 0.2574 | |||
| Treynor Ratio | (0.94) | |||
| Maximum Drawdown | 34.17 | |||
| Value At Risk | (2.88) | |||
| Potential Upside | 4.46 | |||
| Downside Variance | 5.16 | |||
| Semi Variance | 2.87 | |||
| Expected Short fall | (3.22) | |||
| Skewness | 3.96 | |||
| Kurtosis | 21.13 |
Takara Bio Backtested Returns
Takara Bio appears to be relatively risky, given 3 months investment horizon. Takara Bio owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.15, which indicates the firm had a 0.15 % return per unit of risk over the last 3 months. By inspecting Takara Bio's technical indicators, you can evaluate if the expected return of 0.71% is justified by implied risk. Please review Takara Bio's Coefficient Of Variation of 698.42, risk adjusted performance of 0.1215, and Semi Deviation of 1.7 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Takara Bio holds a performance score of 12. The entity has a beta of -0.66, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Takara Bio are expected to decrease at a much lower rate. During the bear market, Takara Bio is likely to outperform the market. Please check Takara Bio's jensen alpha, sortino ratio, maximum drawdown, as well as the relationship between the total risk alpha and treynor ratio , to make a quick decision on whether Takara Bio's existing price patterns will revert.
Auto-correlation | -0.19 |
Insignificant reverse predictability
Takara Bio has insignificant reverse predictability. Overlapping area represents the amount of predictability between Takara Bio time series from 21st of November 2025 to 5th of January 2026 and 5th of January 2026 to 19th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Takara Bio price movement. The serial correlation of -0.19 indicates that over 19.0% of current Takara Bio price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.19 | |
| Spearman Rank Test | -0.24 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Takara Operating Income
Operating Income |
|
Based on the recorded statements, Takara Bio reported net income of 1.04 B. This is 205.03% higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net income for all Germany stocks is 82.32% lower than that of the firm.
Takara Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Takara Bio's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Takara Bio could also be used in its relative valuation, which is a method of valuing Takara Bio by comparing valuation metrics of similar companies.Takara Bio is currently under evaluation in net income category among its peers.
Takara Fundamentals
| Return On Equity | -0.068 | ||||
| Return On Asset | -0.0053 | ||||
| Profit Margin | (0.16) % | ||||
| Operating Margin | (0.26) % | ||||
| Current Valuation | 577.07 M | ||||
| Shares Outstanding | 120.42 M | ||||
| Shares Owned By Insiders | 61.73 % | ||||
| Shares Owned By Institutions | 7.22 % | ||||
| Price To Earning | 52.31 X | ||||
| Price To Book | 1.08 X | ||||
| Price To Sales | 0.02 X | ||||
| Revenue | 45.04 B | ||||
| Gross Profit | 23.84 B | ||||
| EBITDA | 3.98 B | ||||
| Net Income | 1.04 B | ||||
| Cash And Equivalents | 31.49 B | ||||
| Cash Per Share | 261.48 X | ||||
| Total Debt | 9.49 B | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 3.30 X | ||||
| Book Value Per Share | 4.62 X | ||||
| Cash Flow From Operations | 5.84 B | ||||
| Earnings Per Share | (0.29) X | ||||
| Number Of Employees | 1.78 K | ||||
| Beta | 0.37 | ||||
| Market Capitalization | 793.86 M | ||||
| Total Asset | 125.33 B | ||||
| Retained Earnings | 52.47 B | ||||
| Working Capital | 50.55 B | ||||
| Annual Yield | 0.02 % | ||||
| Five Year Return | 0.25 % | ||||
| Net Asset | 125.33 B | ||||
| Last Dividend Paid | 17.0 |
About Takara Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Takara Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Takara Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Takara Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Takara Stock
Takara Bio financial ratios help investors to determine whether Takara Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Takara with respect to the benefits of owning Takara Bio security.